Sage Therapeutics
SAGE
SAGE was delisted on the 30th of July, 2025.
52 hedge funds and large institutions have $596M invested in Sage Therapeutics in 2014 Q3 according to their latest regulatory filings, with 52 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
+$338M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$112M |
| 3 |
O
OrbiMed
New York
|
+$15.6M |
| 4 |
DM
Deerfield Management
New York
|
+$13.1M |
| 5 |
RIM
RS Investment Management
San Francisco,
California
|
+$8.38M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Creative Planning
Overland Park,
Kansas
| $3K | +$2.9K | +100 | New |
|
|
KTC
52
Kistler-Tiffany Companies
Berwyn,
Pennsylvania
| – | +$116 | +4 | New |
|
SAGE Hedge Fund Activity: Q3 2014 in Review
52 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q3 2014, worth a combined $596M.
Buyers outnumbered sellers: 52 funds opened new SAGE positions and 0 closed out — a net gain of 52 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Third Rock Ventures, opening a new position worth an estimated $338M.
- 52 institutional investors held Sage Therapeutics (SAGE) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $596M of Sage Therapeutics stock for Q3 2014.
- 52 funds opened new Sage Therapeutics positions in Q3 2014 and 0 closed out, a net change of +52 holders.
- The largest Sage Therapeutics buyer in Q3 2014 was Third Rock Ventures, an estimated $338M added.
Based on aggregated 13F filings for Q3 2014.